Skip to main content
Start triage

Start triage first, then route to emergency care.

Start symptom intake Emergency vets near you

Need urgent help? Start triage first, then route to emergency care.

Start symptom intake Emergency vets near you

Roxee Meds Catalog

Cefovecin

Medication catalog facts with explicit FDA-approval, off-label, source-limited, and safety context.

Both Catalog complete FDA data linked Rx required Powder Multiple FDA sponsors Official label facts Owner quick guide first
Start Symptom Intake Talk to a Vet / Find a Vet Near You

Veterinary professional?

Showing simplified owner view. Switch to Vet View for full technical detail.

Data freshness

Storefront facts
Catalog refreshed
Apr 22, 2026, 10:07 a.m.

These are the storefront facts Roxee uses on browse cards and quick facts.

FDA applications
FDA application data refreshed
May 5, 2026, 10:00 a.m.

Sponsor, product, and application records imported from Animal Drugs @ FDA.

Safety reports
Safety data refreshed
May 5, 2026, 10:01 a.m.

openFDA reaction terms and case summaries are supporting evidence, not proof of causality.

Source timing details
Source timing details
  • Storefront facts: Source Roxee | Refreshed Apr 22, 2026, 10:07 AM UTC
    The storefront fact projection used for browse cards and quick facts.
  • Animal Drugs @ FDA: Source FDA | Refreshed May 5, 2026, 10:00 AM UTC
    Applications/products are imported from FDA export data.
  • Animal Drugs @ FDA previews: Source FDA | Refreshed Feb 9, 2026, 3:05 AM UTC
    Label highlights/doc links are fetched from FDA preview endpoints.
  • openFDA reaction terms: Source FDA openFDA | Refreshed May 5, 2026, 10:04 AM UTC
  • openFDA case summaries: Source FDA openFDA | Refreshed May 5, 2026, 10:04 AM UTC

Evidence

Reviewed / Updated / Sources

Reviewed by: Not available

Last reviewed: April 15, 2026

Updated: April 15, 2026, 10:04 AM UTC

Sources:
Image coming soon
Cefovecin

Cefovecin

Drug type: Generic ingredient • Generic profile • No FDA branded products linked

Both Powder Rx required 100% storefront ready

Species: Both

Manufacturer: Multiple FDA sponsors

Medication Snapshot

Merged from the current Roxee medication system with field-level provenance, freshness, and completeness tracking.

Cefovecin

For the treatment of skin infections (wounds and abscesses) in cats caused by susceptible strains of Pasteurella multocida . For the treatment of skin infections (secondary superficial pyoderma, abscesses, and wounds) in dogs caused by susceptible strains of Staphylococcus intermedius and Streptococcus canis (Group G). Species commonly shown: Both, Dog, No Use Class Stated Or Implied, Cat, No Use Class Stated Or Implied.

Generic name
Cefovecin
Brand names
Convenia®, Cefovecin Sodium for Injection
Manufacturer
Multiple FDA sponsors
Species
Both, Dog, No Use Class Stated Or Implied, Cat, No Use Class Stated Or Implied
Dosage forms
Powder, Lyophilized powder for injection
Prescription
Prescription required
Completeness
100%
Validation
Complete
Brand names
Convenia® Cefovecin Sodium for Injection
Dosage forms
Powder Lyophilized powder for injection

Indications / Uses

For the treatment of skin infections (wounds and abscesses) in cats caused by susceptible strains of Pasteurella multocida . For the treatment of skin infections (secondary superficial pyoderma, abscesses, and wounds) in dogs caused by susceptible strains of Staphylococcus intermedius and Streptococcus canis (Group G).

Warnings / Contraindications

Federal law restricts this drug to use by or on the order of a licensed veterinarian. For subcutaneous use in dogs and cats only. Federal law restricts this drug to use by or on the order of a licensed veterinarian. Maximum treatment should not exceed 2 injections. For subcutaneous use in dogs and cats only.

  • Federal law restricts this drug to use by or on the order of a licensed veterinarian. For subcutaneous use in dogs and cats only. Federal law restricts this drug to use by or on the order of a licensed veterinarian. Maximum treatment should not exceed 2 injections. For subcutaneous use in dogs and cats only.

Side Effects

Top reported reactions (openFDA): Vomiting, Lethargy (see also Central nervous system depression in 'Neurological'), Death, Anorexia, Diarrhoea, Not eating.

FAQ

Both, Dog, No Use Class Stated Or Implied, Cat, No Use Class Stated Or Implied

Yes. Roxee shows this as prescription-only.

Powder, Lyophilized powder for injection

Related Conditions

Abscesses (cat bite abscess) Pyoderma (superficial/deep)

Source Transparency

Add to My Pet's Meds

Choose a pet, confirm current or past, and optionally add reminder notes.

Sign in to save this medication to your pet profile.

Sign in to continue

Pet Owner Quick Guide

Start here first for the safest next-step summary before the deeper medication detail.

Used for:

For the treatment of skin infections (secondary superficial pyoderma, abscesses, and wounds) in dogs caused by susceptible strains of Staphylococcus intermedius and Streptococcus canis (Group G).

Dosing note:

Exact dosing depends on your pet's species, weight, and health status. Use your veterinarian's instructions for the exact dose and schedule.

What to watch for:

  • For subcutaneous use in dogs and cats only
  • Maximum treatment should not exceed 2 injections
  • wobbly/unsteady walking (1 reports)
  • Loss of appetite (1 reports)
  • Death (1 reports)

When to call the vet:

  • Repeated vomiting or diarrhea.
  • Severe lethargy (hard to wake, very low energy).
  • Collapse or fainting.
  • Trouble breathing.
  • Facial swelling or hives.
  • Blood in vomit or stool.

Regulatory restrictions are shown in Vet View.

What to tell or ask your vet today:

  • Is this medicine the right fit for my pet’s current symptoms?
  • Which warning signs mean I should call back right away?
  • How should I handle missed doses or refusal to take the medicine?
Major cautions & emergency warning signs

Side effects to monitor:

  • For subcutaneous use in dogs and cats only
  • Maximum treatment should not exceed 2 injections
  • wobbly/unsteady walking
  • Loss of appetite
  • Death

Most reported reactions:

  • Unsteady walking (ataxia) (1 reports)
  • Loss of appetite (1 reports)
  • Death (1 reports)

Emergency warning signs:

  • Repeated vomiting or diarrhea.
  • Severe lethargy (hard to wake, very low energy).
  • Collapse or fainting.
  • Trouble breathing.
Talk to a Vet / Find a Vet Near You Start Symptom Intake

Quick Facts

Official label facts first, then secondary summaries. Marketing content is separated below.

Species: Both
Manufacturer: Multiple FDA sponsors
Form: Lyophilized powder for injection, Powder
Identifiers:
ANADA: 200812 NADA: 141285 NDC Package: 17033-002-01 NDC Package: 54771-1520-1 NDC Product: 17033 NDC Product: 54771
Source metadata:

Warnings / Contraindications

Federal law restricts this drug to use by or on the order of a licensed veterinarian. For subcutaneous use in dogs and cats only. Federal law restricts this drug to use by or on the order of a licensed veterinarian. Maximum treatment should not exceed 2 injections. For subcutaneous use in dogs and cats only.

  • High: Federal law restricts this drug to use by or on the order of a licensed veterinarian. For subcutaneous use in dogs and cats only. Federal law restricts this drug to use by or on the order of a licensed veterinarian. Maximum treatment should not exceed 2 injections. For subcutaneous use in dogs and cats only.
Source metadata:

Adverse Reactions

Snapshot first, detailed rows second. This section summarizes signal data and is not a diagnosis.

Tap or hover a reaction to see what it means in plain language.

Tracked signals
32
Reported cases
32
Serious reports
28
Species represented
2
Grouped by Body System
Digestive (3) · Loss of appetite, Bloody diarrhoea, Blood in vomit Skin & allergy (3) · Hair loss at application site, Biting - pruritus, Application site hair loss Neurologic (1) · Unsteady walking (ataxia) Behavior (1) · Behavioral disorder (unspecified) Other (24) · Death, Crust, Confusion
Most Reported Reactions
Reaction Body system Cases Species Serious cases
Neurologic 1 Cat 1
Digestive 1 Cat 1
Other 1 Dog 1
Other 1 Cat 1
Other 1 Dog 1
Other 1 Cat 1
Other 1 Dog 1
Other 1 Cat 1

Species coverage: Cat (24) Dog (8)

View detailed reaction table
Reaction Body system Species Seriousness Frequency Reports
Neurologic Cat Serious - 1
Digestive Cat Serious - 1
Skin & allergy Cat Non-serious - 1
Other Dog Serious - 1
Other Cat Serious - 1
Other Dog Serious - 1
Other Cat Serious - 1
Other Dog Serious - 1
Other Cat Serious - 1
Other Cat Serious - 1
Other Cat Serious - 1
Other Cat Serious - 1
Digestive Cat Serious - 1
Digestive Cat Serious - 1
Other Cat Serious - 1
Skin & allergy Cat Non-serious - 1
Other Cat Serious - 1
Behavior Cat Serious - 1
Other Cat Serious - 1
Other Dog Serious - 1
Other Cat Serious - 1
Other Dog Serious - 1
Other Cat Non-serious - 1
Skin & allergy Cat Non-serious - 1
Other Cat Serious - 1
Other Dog Serious - 1
Other Cat Serious - 1
Other Dog Serious - 1
Other Cat Serious - 1
Other Cat Serious - 1
Other Cat Serious - 1
Other Dog Serious - 1
Source metadata:

Documents

Owner handouts and official technical documents open on-page first, with the original source still one click away.

Owner handouts

0
No owner handouts linked yet.

Official label / PI

0
No official label or package insert links yet.

SPL

2

FOI

2

Cefovecin Sodium for Injection

SPL · SPL

Open original
FDA Structured Product Label

Cefovecin Sodium for Injection

Rendered from Roxee's cached FDA SPL package contents for on-page reading. Use Open original for the raw FDA ZIP/XML source.

Sponsor
Qilu Animal Health Products Co., Ltd.
ANADA
200-812
Status
RX
Form
Lyophilized powder for injection
Route
Subcutaneous
Composition / specifications
Each mL of reconstituted lyophile contains 80 mg of cefovecin as the sodium salt

Dogs

Indication

For the treatment of skin infections (secondary superficial pyoderma, abscesses, and wounds) in dogs caused by susceptible strains of Staphylococcus intermedius and Streptococcus canis (Group G).

Dosage

Administer 3.6 mg/pound (lb) (8 mg/kilograms (kg)) body weight as a single subcutaneous injection. A second subcutaneous injection of 3.6 mg/lb (8 mg/kg) may be administered if response to therapy is not complete.

Cats

Indication

For the treatment of skin infections (wounds and abscesses) in cats caused by susceptible strains of Pasteurella multocida.

Dosage

Administer 3.6 mg/lb (8 mg/kg) body weight as a single, one-time subcutaneous injection.

Convenia®

SPL · SPL

Open original
FDA Structured Product Label

Convenia®

Rendered from Roxee's cached FDA SPL package contents for on-page reading. Use Open original for the raw FDA ZIP/XML source.

Sponsor
Zoetis Inc.
NADA
141-285
Status
RX
Form
Powder
Route
Subcutaneous
Species
Dog, No Use Class Stated Or Implied • Cat, No Use Class Stated Or Implied
Composition / specifications
Each milliliter of constituted solution contains 80 milligrams cefovecin as the sodium salt.

Cats

Indication
For the treatment of skin infections (wounds and abscesses) in cats caused by susceptible strains of Pasteurella multocida.
Dosage
Administer 3.6 mg/lb (8 mg/kg) body weight as a single, one-time subcutaneous injection.
Limitations
Federal law restricts this drug to use by or on the order of a licensed veterinarian. For subcutaneous use in dogs and cats only.

Dogs

Indication
For the treatment of skin infections (secondary superficial pyoderma, abscesses, and wounds) in dogs caused by susceptible strains of Staphylococcus intermedius and Streptococcus canis (Group G).
Dosage
Administer 3.6 mg/lb (8 mg/kg) body weight as a single subcutaneous injection. A second subcutaneous injection of 3.6 mg/lb (8 mg/kg) may be administered if response to therapy is not complete.
Limitations
Federal law restricts this drug to use by or on the order of a licensed veterinarian. Maximum treatment should not exceed 2 injections. For subcutaneous use in dogs and cats only.

FOI Summary oA 200-812 Approved June 24, 2025.pdf

FOI · FOI

Open original

ucm062340.pdf

FOI · FOI

Open original
Source metadata:
Veterinary reference (advanced)

Canonical medication sections are above. This legacy block remains available for deeper cross-reference without cluttering the primary workflow.

At a Glance

Quick facts and links to official labeling and safety signals.

Data freshness
  • Storefront facts: Source Roxee | Refreshed Apr 22, 2026, 10:07 AM UTC
    The storefront fact projection used for browse cards and quick facts.
  • Animal Drugs @ FDA: Source FDA | Refreshed May 5, 2026, 10:00 AM UTC
    Applications/products are imported from FDA export data.
  • Animal Drugs @ FDA previews: Source FDA | Refreshed Feb 9, 2026, 3:05 AM UTC
    Label highlights/doc links are fetched from FDA preview endpoints.
  • openFDA reaction terms: Source FDA openFDA | Refreshed May 5, 2026, 10:04 AM UTC
  • openFDA case summaries: Source FDA openFDA | Refreshed May 5, 2026, 10:04 AM UTC
Official (FDA)
Identity: Generic ingredient • No FDA branded products linked
No official FDA brand rows linked yet for this ingredient.
Case-reported brands (openFDA): MSK
Catalog species: Both • FDA-labeled species: Cat, Dog
Rx/OTC: RX
Form/route: Lyophilized powder for injection, Powder • Subcutaneous
Applications: ANADA 200-812 • NADA 141-285
Documents: 2 (FOI: 2) • SPL: 2 • Label highlights • Official documents
Safety (openFDA)
Top reactions: Dog 35 • Cat 130 • View
Case summaries: 31 (showing 8) • View
openFDA reports are unverified and do not prove causation.
Explore
Linked using: Fda_Label (0.95), Fda_Label (0.95)
Diagnosis Codes

Diagnosis-code mappings are not available for this medication yet.

Counseling and Monitoring Highlights

Global Pet owner/Vet mode is controlled in the header. This section avoids duplicate in-page persona tabs.

Owner-facing counseling points
  • Federal law restricts this drug to use by or on the order of a licensed veterinarian. For subcutaneous use in dogs and cats only. Federal law restricts this drug to use by or on the order of a licensed veterinarian. Maximum treatment should not exceed 2 injections. For subcutaneous use in dogs and cats only. (Contraindication, High)
Top reaction signals
Unsteady walking (ataxia) (1) Loss of appetite (1) Death (1) Crust (1) Confusion (1) Collapse NOS (1) Cellulitis (1) Cardiorespiratory arrest (1)

Identifiers & Packages

Normalized identifiers (NDC/NADA/ANADA) and package metadata from regulator listings.

Identifiers
ANADA: 200812 NADA: 141285 NDC Package: 17033-002-01 NDC Package: 54771-1520-1 NDC Product: 17033 NDC Product: 54771
Package NDC Product NDC Form / Route Status
17033-002-01 17033 -
54771-1520-1 54771 -

Enriched Documents

Documents are tiered by source trust: Official, Clinical, Manufacturer, Marketing.

Data Sources & Change Log

Every non-trivial field is expected to include provenance and update timestamps.

Official 21 Clinical 9 Manufacturer 0 Marketing 0
Current Field Facts
  • contraindications: Federal law restricts this drug to use by or on the order of a licensed veterinarian. For subcutaneous use in dogs and cats only. Federal law restricts this dr… (Clinical, 2026-04-15)
  • contraindications: Federal law restricts this drug to use by or on the order of a licensed veterinarian. For subcutaneous use in dogs and cats only. Federal law restricts this dr… (Clinical, 2026-04-15)
  • contraindications: Federal law restricts this drug to use by or on the order of a licensed veterinarian. For subcutaneous use in dogs and cats only. Federal law restricts this dr… (Clinical, 2026-04-11)
  • monitoring: Monitor blood glucose and ketones, hydration status, appetite, and clinical response at regular intervals. (Clinical, 2026-04-16)
  • monitoring: Monitor blood glucose and ketones, hydration status, appetite, and clinical response at regular intervals. (Clinical, 2026-04-15)
  • side_effects: Top reported reactions (openFDA): Vomiting, Lethargy (see also Central nervous system depression in 'Neurological'), Death, Anorexia, Diarrhoea, Not eating. (Clinical, 2026-04-11)
  • usage: For the treatment of skin infections (wounds and abscesses) in cats caused by susceptible strains of Pasteurella multocida . For the treatment of skin infectio… (Clinical, 2026-04-15)
  • usage: For the treatment of skin infections (wounds and abscesses) in cats caused by susceptible strains of Pasteurella multocida . For the treatment of skin infectio… (Clinical, 2026-04-15)
  • usage: For the treatment of skin infections (wounds and abscesses) in cats caused by susceptible strains of Pasteurella multocida . For the treatment of skin infectio… (Clinical, 2026-04-11)
  • contraindications: Federal law restricts this drug to use by or on the order of a licensed veterinarian. For subcutaneous use in dogs and cats only. Federal law restricts this dr… (Official, 2026-04-22)
  • contraindications: Federal law restricts this drug to use by or on the order of a licensed veterinarian. For subcutaneous use in dogs and cats only. Federal law restricts this dr… (Official, 2026-02-12)
  • indications: Dogs:Â For the treatment of skin infections (secondary superficial pyoderma, abscesses, and wounds) in dogs caused by susceptible strains of Staphylococcus int… (Official, 2026-05-05)
  • indications: Dogs:Â For the treatment of skin infections (secondary superficial pyoderma, abscesses, and wounds) in dogs caused by susceptible strains of Staphylococcus int… (Official, 2026-05-03)
  • indications: Dogs:Â For the treatment of skin infections (secondary superficial pyoderma, abscesses, and wounds) in dogs caused by susceptible strains of Staphylococcus int… (Official, 2026-05-02)
  • indications: Dogs:Â For the treatment of skin infections (secondary superficial pyoderma, abscesses, and wounds) in dogs caused by susceptible strains of Staphylococcus int… (Official, 2026-04-29)
  • indications: Dogs:Â For the treatment of skin infections (secondary superficial pyoderma, abscesses, and wounds) in dogs caused by susceptible strains of Staphylococcus int… (Official, 2026-04-28)
  • indications: Dogs:Â For the treatment of skin infections (secondary superficial pyoderma, abscesses, and wounds) in dogs caused by susceptible strains of Staphylococcus int… (Official, 2026-04-27)
  • indications: Dogs:Â For the treatment of skin infections (secondary superficial pyoderma, abscesses, and wounds) in dogs caused by susceptible strains of Staphylococcus int… (Official, 2026-04-26)
  • indications: Dogs:Â For the treatment of skin infections (secondary superficial pyoderma, abscesses, and wounds) in dogs caused by susceptible strains of Staphylococcus int… (Official, 2026-04-25)
  • indications: Dogs:Â For the treatment of skin infections (secondary superficial pyoderma, abscesses, and wounds) in dogs caused by susceptible strains of Staphylococcus int… (Official, 2026-04-22)
Recent Revisions
  • side_effects updated 2026-04-22 10:07 by etl_backfill • Backfilled from existing medication fields
  • contraindications updated 2026-04-22 10:07 by etl_backfill • Backfilled from existing medication fields
  • usage updated 2026-04-22 10:07 by etl_backfill • Backfilled from existing medication fields
  • monitoring updated 2026-04-16 13:27 by curated_loader • Clinical monitoring context for feline diabetes management.
  • usage updated 2026-04-16 13:27 by curated_loader • Usage statement from FDA warning letter and approved-product context.
  • drug_profile_type updated 2026-04-16 13:27 by curated_loader • FDA source confirms Senvelgo as a branded approved product.
  • manufacturer_name updated 2026-04-16 13:27 by curated_loader • FDA warning letter identifies the approved sponsor/manufacturer.
  • brand_names updated 2026-04-16 13:27 by curated_loader • FDA warning letter references Senvelgo as the approved animal drug.
  • approval_reference updated 2026-04-16 13:27 by curated_loader • Official FDA application reference for Senvelgo.
  • side_effects updated 2026-04-15 10:06 by etl_backfill • Backfilled from existing medication fields
  • contraindications updated 2026-04-15 10:06 by etl_backfill • Backfilled from existing medication fields
  • usage updated 2026-04-15 10:06 by etl_backfill • Backfilled from existing medication fields
  • monitoring updated 2026-04-15 10:06 by curated_loader • Clinical monitoring context for feline diabetes management.
  • usage updated 2026-04-15 10:06 by curated_loader • Usage statement from FDA warning letter and approved-product context.
  • drug_profile_type updated 2026-04-15 10:06 by curated_loader • FDA source confirms Senvelgo as a branded approved product.
  • manufacturer_name updated 2026-04-15 10:06 by curated_loader • FDA warning letter identifies the approved sponsor/manufacturer.
  • brand_names updated 2026-04-15 10:06 by curated_loader • FDA warning letter references Senvelgo as the approved animal drug.
  • approval_reference updated 2026-04-15 10:06 by curated_loader • Official FDA application reference for Senvelgo.
  • side_effects updated 2026-04-15 10:04 by etl_backfill • Backfilled from existing medication fields
  • contraindications updated 2026-04-15 10:04 by etl_backfill • Backfilled from existing medication fields

FDA Products & Applications (Animal Drugs @ FDA)

Official sponsor/proprietary-name/application-status records linked by active ingredient.

Product Sponsor Application Status Published
Cefovecin Sodium for Injection
RX
Cefovecin sodium
Lyophilized powder for injection • Subcutaneous
Label highlights
Official documents
Qilu Animal Health Products Co., Ltd. ANADA 200-812 Approved Jul 1, 2025
Convenia®
RX
Cefovecin sodium
Powder • Subcutaneous
Label highlights
Official documents
Zoetis Inc. NADA 141-285 Approved Oct 2, 2017

Data source: FDA Animal Drugs @ FDA (public search export).

What It's For (FDA Label Highlights)

Extracted from FDA Animal Drugs @ FDA product labeling. Always confirm details with your veterinarian.

Composition / specifications
Each mL of reconstituted lyophile contains 80 mg of cefovecin as the sodium salt
Dogs
Indication

For the treatment of skin infections (secondary superficial pyoderma, abscesses, and wounds) in dogs caused by susceptible strains of Staphylococcus intermedius and Streptococcus canis (Group G).

Dosage

Administer 3.6 mg/pound (lb) (8 mg/kilograms (kg)) body weight as a single subcutaneous injection. A second subcutaneous injection of 3.6 mg/lb (8 mg/kg) may be administered if response to therapy is not complete.

Limitations
Cats
Indication

For the treatment of skin infections (wounds and abscesses) in cats caused by susceptible strains of Pasteurella multocida.

Dosage

Administer 3.6 mg/lb (8 mg/kg) body weight as a single, one-time subcutaneous injection.

Limitations

FDA page: Open in Animal Drugs @ FDA

Species: Dog, No Use Class Stated Or Implied • Cat, No Use Class Stated Or Implied
Composition / specifications
Each milliliter of constituted solution contains 80 milligrams cefovecin as the sodium salt.
Cats
Indication
For the treatment of skin infections (wounds and abscesses) in cats caused by susceptible strains of Pasteurella multocida.
Dosage
Administer 3.6 mg/lb (8 mg/kg) body weight as a single, one-time subcutaneous injection.
Limitations
Federal law restricts this drug to use by or on the order of a licensed veterinarian. For subcutaneous use in dogs and cats only.
Dogs
Indication
For the treatment of skin infections (secondary superficial pyoderma, abscesses, and wounds) in dogs caused by susceptible strains of Staphylococcus intermedius and Streptococcus canis (Group G).
Dosage
Administer 3.6 mg/lb (8 mg/kg) body weight as a single subcutaneous injection. A second subcutaneous injection of 3.6 mg/lb (8 mg/kg) may be administered if response to therapy is not complete.
Limitations
Federal law restricts this drug to use by or on the order of a licensed veterinarian. Maximum treatment should not exceed 2 injections. For subcutaneous use in dogs and cats only.

FDA page: Open in Animal Drugs @ FDA

Usage

For the treatment of skin infections (wounds and abscesses) in cats caused by susceptible strains of Pasteurella multocida . For the treatment of skin infections (secondary superficial pyoderma, abscesses, and wounds) in dogs caused by susceptible strains of Staphylococcus intermedius and Streptococcus canis (Group G).

Source: FDA Animal Drugs @ FDA • Reference

Contraindications

Federal law restricts this drug to use by or on the order of a licensed veterinarian. For subcutaneous use in dogs and cats only. Federal law restricts this drug to use by or on the order of a licensed veterinarian. Maximum treatment should not exceed 2 injections. For subcutaneous use in dogs and cats only.

Top Reported Reactions (openFDA)

De-duplicated reaction terms grouped by body system from FDA openFDA reports (not verified; does not prove causation).

Digestive
Loss of appetite (1) • Cat Bloody diarrhoea (1) • Cat Blood in vomit (1) • Cat

Showing top 5 for Digestive.

Skin & allergy
Hair loss at application site (1) • Cat Biting - pruritus (1) • Cat Application site hair loss (1) • Cat

Showing top 5 for Skin & allergy.

Neurologic
Unsteady walking (1) • Cat

Showing top 5 for Neurologic.

Behavior
Behavioral disorder (1) • Cat

Showing top 5 for Behavior.

Other
Death (1) • Dog Crust (1) • Cat Confusion (1) • Dog Collapse NOS (1) • Cat Cellulitis (1) • Dog
Show more (19)
Cardiorespiratory arrest (1) • Cat Cardiac enlargement (1) • Cat Carcinoma NOS (1) • Cat Bloody stool (1) • Cat Blood in urine (1) • Cat Bilirubinuria (1) • Cat Basophilia (1) • Cat Autoimmune disorder NOS (1) • Dog Ascites (1) • Cat Arched back (1) • Dog Application site skin scaling (1) • Cat Anaphylaxis (1) • Cat Anal sac disorder (1) • Dog Anaemia NOS (1) • Cat Abscess NOS (1) • Dog Abnormal ultrasound finding (1) • Cat Abnormal radiograph finding (1) • Cat Abnormal cytology (1) • Cat Abdominal discomfort (1) • Dog

Showing top 5 for Other.

Data source: FDA openFDA Animal & Veterinary adverse event reports.

Adverse Event Case Summaries (openFDA)

These are individual FDA adverse event reports. They are unverified and do not prove the medication caused the reaction.

Cat, Domestic Longhair, Male, 8 year, 4.853 kilogram • Drug: MSK, Injection, Subcutaneous, Dose: 0.48 mL per animal • Reactions: Miliary dermatitis, Skin scab, Itching, Abnormal cytology, Pyoderma… • Outcome: Outcome Unknown

  • Report ID: USA-USFDACVM-2025-US-075203
  • Serious AE: Yes
  • Treated For AE: Yes
  • Sex: Male
  • Age: 8.00 Year
  • Weight: 4.853 Kilogram
  • Case-reported brand: MSK
  • Case-reported manufacturer: MSK
  • Route: Subcutaneous
  • Form: Injection
  • Dose: 0.48 mL per animal
Reactions Reported:
Miliary dermatitis Skin scab Itching Abnormal cytology Pyoderma Partial lack of efficacy Skin lesion NOS Crust Skin sore
Outcomes: Outcome Unknown

Cat, Persian, Male, 12.5 year, 4.4 kilogram • Drug: MSK, Injection, Subcutaneous, Dose: 0.44 mL per animal • Reactions: Intentional misuse, Lack of efficacy - NOS, Death by euthanasia, Gait abnormality, Lumbar pain • Outcome: Euthanized

  • Report ID: USA-USFDACVM-2025-US-075165
  • Serious AE: Yes
  • Treated For AE: Yes
  • Sex: Male
  • Age: 12.50 Year
  • Weight: 4.400 Kilogram
  • Case-reported brand: MSK
  • Case-reported manufacturer: MSK
  • Route: Subcutaneous
  • Form: Injection
  • Dose: 0.44 mL per animal
Reactions Reported:
Intentional misuse Lack of efficacy - NOS Death by euthanasia Gait abnormality Lumbar pain
Outcomes: Euthanized

Cat, Domestic Shorthair, Male, 7 year, 8.618 kilogram • Drug: MSK, Injection, Subcutaneous, Dose: 0.90 mL per animal • Reactions: Injection site hair loss, Reddening of the skin, Weight loss, Skin lesion NOS, Wound… • Outcome: Ongoing

  • Report ID: USA-USFDACVM-2025-US-075379
  • Serious AE: Yes
  • Treated For AE: Yes
  • Sex: Male
  • Age: 7.00 Year
  • Weight: 8.618 Kilogram
  • Case-reported brand: MSK
  • Case-reported manufacturer: MSK
  • Route: Subcutaneous
  • Form: Injection
  • Dose: 0.90 mL per animal
Reactions Reported:
Injection site hair loss Reddening of the skin Weight loss Skin lesion NOS Wound Abnormal cytology Discomfort NOS Skin necrosis Itching Facial swelling (possible allergy) Facial rash
Outcomes: Ongoing

Cat, Domestic Shorthair, Male, 15 year, 8.391 kilogram • Drug: MSK, Injection, Subcutaneous, Frequency: 7 per year • Reactions: Death • Outcome: Died

  • Report ID: USA-USFDACVM-2025-US-075361
  • Serious AE: Yes
  • Treated For AE: No
  • Sex: Male
  • Age: 15.00 Year
  • Weight: 8.391 Kilogram
  • Case-reported brand: MSK
  • Case-reported manufacturer: MSK
  • Route: Subcutaneous
  • Form: Injection
  • Frequency: 7 per year
Reactions Reported:
Death
Outcomes: Died

Cat, Persian, Male, 6 year, 3.751 kilogram • Drug: MSK, Injection, Subcutaneous, Dose: 0.38 mL per animal • Reactions: Death • Outcome: Died

  • Report ID: USA-USFDACVM-2025-US-075247
  • Serious AE: Yes
  • Treated For AE: No
  • Sex: Male
  • Age: 6.00 Year
  • Weight: 3.751 Kilogram
  • Case-reported brand: MSK
  • Case-reported manufacturer: MSK
  • Route: Subcutaneous
  • Form: Injection
  • Dose: 0.38 mL per animal
Reactions Reported:
Death
Outcomes: Died

Cat, Domestic Shorthair, Male, 13 year, 4.717 kilogram • Drug: MSK, Injection, Subcutaneous, Dose: 0.47 mL per animal • Reactions: Diarrhea • Outcome: Ongoing

  • Report ID: USA-USFDACVM-2025-US-075145
  • Serious AE: Yes
  • Treated For AE: Yes
  • Sex: Male
  • Age: 13.00 Year
  • Weight: 4.717 Kilogram
  • Case-reported brand: MSK
  • Case-reported manufacturer: MSK
  • Route: Subcutaneous
  • Form: Injection
  • Dose: 0.47 mL per animal
Reactions Reported:
Diarrhea
Outcomes: Ongoing

Cat, Siamese, Female, 11.75 year, 3.73 kilogram • Drug: MSK, Unknown • Reactions: Application site hair loss, Skin lesion NOS • Outcome: Ongoing

  • Report ID: USA-USFDACVM-2025-US-074804
  • Serious AE: No
  • Treated For AE: Yes
  • Sex: Female
  • Age: 11.75 Year
  • Weight: 3.730 Kilogram
  • Case-reported brand: MSK
  • Case-reported manufacturer: MSK
  • Route: Unknown
Reactions Reported:
Application site hair loss Skin lesion NOS
Outcomes: Ongoing

Cat, Persian, Male, 10.83 year, 4.67 kilogram • Drug: MSK, Subcutaneous • Reactions: Hair loss at application site, Defect Unknown/Not Specified • Outcome: Ongoing

  • Report ID: USA-USFDACVM-2025-US-074803
  • Serious AE: No
  • Treated For AE: No
  • Sex: Male
  • Age: 10.83 Year
  • Weight: 4.670 Kilogram
  • Case-reported brand: MSK
  • Case-reported manufacturer: MSK
  • Route: Subcutaneous
Reactions Reported:
Hair loss at application site Defect Unknown/Not Specified
Outcomes: Ongoing

Data source: FDA openFDA Animal & Veterinary adverse event reports.

Overdose Information

No approved overdose-management text is linked yet. If overdose is suspected, contact a veterinarian or emergency clinic immediately.

Storage & Handling

No approved storage guidance is linked yet for this ingredient. Use manufacturer packaging and veterinary guidance for handling/storage.

Share Your Thoughts

Let others know your experience or advice regarding this medication.

This medication has not been reviewed by a veterinarian yet.